

# Unity in Diversity and the Standardisation of Clinical Pharmacy Services

Editors: Elida Zairina, Junaidi Khotib,  
Chrismawan Ardianto, Syed Azhar Syed Sulaiman,  
Charles D. Sands III and Timothy E. Welty

 CRC Press  
Taylor & Francis Group  
A BALKEMA BOOK

# Unity in Diversity and the Standardisation of Clinical Pharmacy Services

Editors: Elida Zairina, Junaidi Khotib,  
Chrismawan Ardianto, Syed Azhar Syed Sulaiman,  
Charles D. Sands III and Timothy E. Welty

 CRC Press  
Taylor & Francis Group  
A BALKEMA BOOK

UNITY IN DIVERSITY AND THE STANDARDISATION OF CLINICAL  
PHARMACY SERVICES



**Taylor & Francis**

Taylor & Francis Group

<http://taylorandfrancis.com>

PROCEEDINGS OF THE 17<sup>TH</sup> ASIAN CONFERENCE ON CLINICAL PHARMACY (ACCP 2017),  
28–30 JULY 2017, YOGYAKARTA, INDONESIA

# Unity in Diversity and the Standardisation of Clinical Pharmacy Services

*Editors*

**Elida Zairina**

*Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga,  
Surabaya, Indonesia*

**Junaidi Khotib & Chrismawan Ardianto**

*Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga,  
Surabaya, Indonesia*

**Syed Azhar Syed Sulaiman**

*Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains  
Malaysia, Penang, Malaysia*

**Charles D. Sands III**

*(Formerly) McWhorter School of Pharmacy, College of Health Sciences, Samford  
University, Birmingham, Alabama, USA*

**Timothy E. Welty**

*Department of Clinical Sciences, College of Pharmacy and Health Sciences, Drake  
University, Iowa, USA*



**CRC Press**

Taylor & Francis Group  
Boca Raton London New York Leiden

CRC Press is an imprint of the  
Taylor & Francis Group, an **informa** business

A BALKEMA BOOK

*CRC Press/Balkema is an imprint of the Taylor & Francis Group, an informa business*

© 2018 Taylor & Francis Group, London, UK

Typeset by V Publishing Solutions Pvt Ltd., Chennai, India  
Printed and bound in Great Britain by CPI Group (UK) Ltd, Croydon, CR0 4YY

All rights reserved. No part of this publication or the information contained herein may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, by photocopying, recording or otherwise, without written prior permission from the publisher.

Although all care is taken to ensure integrity and the quality of this publication and the information herein, no responsibility is assumed by the publishers nor the author for any damage to the property or persons as a result of operation or use of this publication and/or the information contained herein.

Published by: CRC Press/Balkema  
Schipholweg 107C, 2316 XC Leiden, The Netherlands  
e-mail: [Pub.NL@taylorandfrancis.com](mailto:Pub.NL@taylorandfrancis.com)  
[www.crcpress.com](http://www.crcpress.com) – [www.taylorandfrancis.com](http://www.taylorandfrancis.com)

ISBN: 978-1-138-08172-7 (Hbk)  
ISBN: 978-1-315-11275-6 (eBook)

## Table of contents

Preface	ix
Organizing committee	xi
Keynote speakers	xv
Plenary speakers	xvii
List of symposium speakers	xix
Medication management system in several care homes in Surabaya <i>G.N.V. Achmad, G. Nugraheni, W. Utami, S. Hardiyanti, S. Danutri, D.K. Lestari, Muhliseh &amp; A.T. Mahardika</i>	1
Effectiveness of decision aid on knowledge, decision conflict, and outcome in diabetic patients <i>L. Aditama &amp; F. Yulia</i>	7
Self-esteem scale: Translation and validation in Malaysian adults living with asthma <i>S. Ahmad, M. Qamar, F.A. Shaikh, N.E. Ismail, A.I. Ismail &amp; M.A.M. Zim</i>	13
Factors affecting mortality among patients undergoing hemodialysis in Sudan <i>O. Amir, A. Sarriff, A.H. Khan, M.B. Abdelraheem &amp; B. Nors'adah</i>	19
Evaluating the effectiveness of filgrastim in patients with solid cancer <i>E.N. Anggraeny, F. Rahmawati &amp; K.W. Taroeno-Hariadi</i>	27
Building care of hypertensive patients in reducing sodium intake in Banjarmasin <i>H. Ariyani, Akrom &amp; R. Alfian</i>	33
Effect of glibenclamide on glycemic control in the presence of sodium diclofenac <i>T. Aryani, M.N. Zamzamah, Z. Izzah &amp; M. Rahmadi</i>	41
A drug utilization study of antibiotics in patients with osteomyelitis <i>A.S. Budiati, K.D. Kurdiana, B.S. Zulkarnain, H. Suroto &amp; R. Diniya</i>	45
Factors influencing trastuzumab cardiotoxicity in breast cancer: A case-control study <i>C. Cherachat, C. Sukkasem, C. Somwangprasert, S. Pornbunjerd, N. Parinyanitikul &amp; K. Tewthanom</i>	51
Transdermal patch loading diclofenac sodium for anti-inflammation therapy using a rat paw oedema model <i>P. Christanto, Ismaeni, A. Miatmoko &amp; E. Hendradi</i>	55
Ethambutol-induced optic neuropathy in diabetic patients with tuberculosis <i>M. Djunaedi, U. Athiyah, Y. Priyandani &amp; S.A.S. Sulaiman</i>	61
Identification of clinical specimens isolated from neonates <i>M. Djunaedi, S.A.S. Sulaiman, A. Sarriff, N.B.A. Aziz &amp; Habsah</i>	65
Effect of coenzyme Q10 on the malondialdehyde level and exercise performance of male runners in Jakarta <i>S. Gunawan, Purwastyastuti, F.D. Suyatna &amp; E.I. Ilyas</i>	73
Compatibility of selected inotropic drugs in a syringe <i>S. Hanifah, R.A. Kennedy &amp; P.A. Ball</i>	81

Ward pharmacist workload analysis in an Indonesian class A hospital <i>A.L. Hariadini, W. Utami &amp; A. Rahem</i>	87
Effect of LD50 of ethanolic leaf extract from <i>Ipomoea reptans</i> Poir. in rats <i>F. Hayati, R. Istikharah, S. Arifah &amp; D. Nurhasanah</i>	95
Oral indomethacin versus oral paracetamol for patent ductus arteriosus closure in neonates <i>N.A. Ibrahim, N.C. Umar, M.C.H. Chi'ing, P.E. Stephen &amp; P. Anandkrishnan</i>	99
Clinical trial of Jamu X on blood glucosa and HbA1C in patients with type 2 diabetes mellitus <i>Z. Ikawati, M. Eko Cahyanto, N.R. Sholehah &amp; N. Atikah</i>	107
Management of carbamate or organophosphate intoxication at a high care unit <i>Z. Izzah, T. Aryani, R. Rodhika &amp; Lestiono</i>	113
Development of an antidepressant e-learning tool for pharmacology education <i>A. Karaksha, M. Dharmesti, A.K. Davey, G. Grant, S.A. Dukie, H. Budianto, E.V. Mutiara, V. Marina, I. Puspitaningrum &amp; A. Shollina</i>	119
Effectiveness of nimodipine on non-traumatic subarachnoid hemorrhage based on computed tomography angiography <i>J. Khotib, S.S. Ganesen &amp; A.F. Sani</i>	125
Study of pediatric compounded drug prescriptions in a health care facility in Bandung <i>F. Lestari, Y. Aryanti &amp; U. Yuniarni</i>	133
Efficacy of honey vinegar in hyperlipidemic rats ( <i>Rattus norvegicus</i> ) <i>E.W. Lucia, K. Lidya &amp; T. Annisa</i>	139
Improving the competence of pharmacist students through international lecturers <i>O.R. Mafrihah, S. Hanifah, C.P. Sari, P.A. Ball &amp; H. Morrissey</i>	143
The effectiveness evaluation of antiretroviral therapy in Mangusada Hospital Bali <i>H. Meriyani, N.N.W. Udayani &amp; K.A. Adrianta</i>	149
Drug therapy problems in pediatric and geriatric patients at Farmasi Airlangga Pharmacy <i>Mufarrihah, D.M. Machfud, V.D.A. Purworini, A. Yuda, Y. Priyandani &amp; Y. Nita</i>	153
PCR primer design for detection of SNPs in SLC22A1 rs683369 encoding OCT1 as the main transporter of metformin <i>A.A. Mukminatun, V.D.A. Ningrum &amp; R. Istikharah</i>	161
Pharmacist-patient communication: An observational study of characteristic information <i>I. Mulyono, S. Irawati, A. Pratidina &amp; M. Claramita</i>	167
Multidrug resistance-1 gene variants in pediatric leukemia in Bali <i>R. Niruri, N.L. Ulandari, S.C. Yowani, I. Narayani &amp; K. Ariawati</i>	171
Medication adherence in the elderly with chronic diseases using the Adherence to Refill and Medication Scale (ARMS) <i>Y. Nita, F.M. Saputra, S. Damayanti, P.I. Pratiwi, R. Zukhairah, A. Sulistyarini &amp; Y. Priyandani</i>	175
Direct non-medical costs of patients with cervical cancer who underwent chemotherapy <i>R. Noviyani, P.A. Indrayathi, H. Thabrany, Andrijono, I.N.G. Budiana &amp; K. Tumas</i>	179
Factors influencing correct measurements of liquid medicines by consumers <i>G. Nugraheni &amp; G.N.V. Achmad</i>	185
The correlation of service quality and complaint handling with patient satisfaction <i>R.A. Oetari, M.E. Sariwatin, H. Basir &amp; C. Wiedyaningsih</i>	189
Assessment of medication safety among Filipino pharmacists <i>R.C. Ongpoy Jr., P.P. David, R.C. Ongpoy, M.D.U. Dean &amp; A.D. Atienza</i>	195
Effect of the combination of <i>Typhonium flagelliforme</i> Lodd. (Blume) and <i>Phyllanthus niruri</i> Linn. on the immune system <i>S.S. Pangestika, A.P. Gani, A. Yuswanto &amp; R. Murwanti</i>	201



Organophosphate toxicity in red chili farmers, Ciamis, Indonesia <i>D.A. Perwitasari, D. Prasasti, I.W. Arsanti &amp; I.A. Wiraagni</i>	207
Factors affecting the rational use of NSAIDs in self-medication <i>L. Pristianty, G.N.V. Achmad &amp; A. Faturrohmah</i>	213
The influence of adverse reactions of antituberculosis drugs to non-adherence in drug use <i>Y. Priyandani, C.D. Setiawan, A. Yuda, Y. Nita, U. Athiyah, M.B. Qomaruddin &amp; Kuntoro</i>	217
(-)-Epigallocatechin gallate from green tea increases the level of a DNA repair enzyme <i>D.A. Purwanto</i>	223
Perceptions and practices of self-medication among healthcare students <i>M. Qamar, S. Novhazimah, F.A. Shaikh &amp; S. Ahmad</i>	227
Smoking cessation counseling: Perceptions and barriers among community pharmacists <i>M. Qamar, S. Ahmad, K. Poobalan, F.A. Shaikh &amp; M.A. Hammad</i>	233
Factors affecting medication noncompliance in patients with chronic diseases <i>A. Rahem</i>	241
The development and evaluation of a clinical pharmacy course at a pharmacy school in Indonesia <i>F. Rahmawati, D. Wahyono &amp; M. Ihsan</i>	245
Relationship ejection fraction and segment ST-resolution in STEMI patients with streptokinase therapy <i>D.M.N. Ratri, S. Sjamsiah, H.P. Jaya &amp; M. Aminuddin</i>	251
Management of hyponatremia in patients with heart failure: A retrospective study <i>S. Saepudin, P.A. Ball &amp; H. Morrissey</i>	255
Continuous infusion versus intermittent bolus furosemide in heart failure NYHA III-IV <i>Samirah, S. Sjamsiah &amp; M. Yogiarto</i>	261
The effectiveness of empirical and definitive antimicrobial therapy <i>I.P. Sari, R.H. Asdie, T. Nuryastuti, Sugiyono &amp; Sunaryana</i>	265
<i>In vivo</i> analgesic effect of ethanolic extracts of exocarp, mesocarp, and seeds of <i>Carica pubescens</i> <i>H. Sasongko &amp; Sugiyarto</i>	271
Evaluation of knowledge, attitude and perceived barriers towards adverse drug reaction reporting <i>F.A. Shaikh, S. Ahmad, E. Intra, M. Qamar &amp; T.M. Khan</i>	275
Hydroxyethyl starch or gelatin, which is safer for the kidneys? <i>D.W. Shinta, J. Khotib, M. Rahmadi, B. Suprpti, E. Rahardjo &amp; J.K. Wijoyo</i>	281
In silico QSAR of 1-benzoyl-3-benzylurea lead and its analogue compounds as anticancer <i>F. Suhud, C. Effendi &amp; Siswando</i>	287
A study on antiemetics for postoperative nausea and vomiting at Dr. Soetomo Hospital Suharjo <i>M.E.B.M.A. Nazim, B.P. Semedi &amp; R. Diniya</i>	293
Ethanol extract of <i>Annona squamosa</i> L. improves the lipid profile in hyperlipidemia rats <i>R. Sumarny, Y. Sumiyati &amp; D. Maulina</i>	297
The effect of Telmisartan on lipid levels and proinflammatory cytokines in ESRD patients undergoing hemodialysis <i>B. Suprpti, W.P. Nilamsari, Z. Izzah, M. Dhrik &amp; B. Dharma</i>	303
Risk assessment of ADEs: Patient safety incident reports at Ari Canti Hospital in 2016 <i>D.A. Swastini, N.W.S. Wahyuni &amp; K. Widianlara</i>	307
Medication-induced Adverse Drug Reaction (ADR) in the Malaysian elderly population <i>H.M. Taib, Z.A. Zainal, N.M. Ali &amp; R. Hashim</i>	311

Cost-effectiveness analysis of patients with schizophrenia in Madani Hospital <i>M.R. Tandah, A. Mukaddas &amp; W. Handayani</i>	317
Tacrolimus-induced symptomatic hyponatremia after kidney transplantation: A case study <i>T. Verayachankul &amp; J. Tantivit</i>	323
Postoperative pain management in elderly patients: Evaluating the use of analgesics <i>A. Vonna, A. Apriani &amp; Sadli</i>	327
Antimalarial activity and toxicological test of <i>Andrographis paniculata</i> tablets (AS202-01) <i>A. Widyawaruyanti, A.F. Hafid, D.A. Fitriiningtyas, L.S. Lestari, H. Ilmi &amp; I.S. Tantular</i>	333
Socioeconomic status and obesity in an adult rural population in Indonesia <i>A. Widayati, Fenty, D.M. Virginia &amp; P. Hendra</i>	339
A strategic approach to increase the compliance of patients with type 2 diabetes mellitus <i>N. Wulandari, D. Vivianhari &amp; Nurhayati</i>	343
Disposal practices of unused medication among the public in Meradong, Sarawak, Malaysia <i>N.L.C. Yaacob, L.P. Wei, S. Ahmad, F. Naimat &amp; A. Ahmad</i>	349
Drug use and potential drug interaction in the elderly <i>A. Yuda, E.C. Dewi, D.M. Fani, L. Jamila, M. Rakhmawati, K.P.P. Sari, K.P. Ningrum, G.N.V. Achmad &amp; Y. Nita</i>	357
Effects of audiovisual education on the knowledge and adherence of patients with DMT1 <i>L.Y. Yusan, N. Rochmah, A. Rahem &amp; A. Purnamayanti</i>	363
Root extract of <i>Imperata cylindrica</i> L. improves serum nitric oxide levels in diabetic mice <i>A. Zada, J.B. Dewanto, A. Dahlan, D. Dhianawaty, M.R.A.A. Syansunarno, G.R. Mukarromah &amp; N. Anggraeni</i>	367
Medication use during pregnancy in Surabaya: A cross-sectional study <i>E. Zairina, G. Nugraheni, G.N. Veronika Ahmad, A. Yuda, Y. Nita, M.P. Wardhana &amp; K.E. Gumilar</i>	371
Eyedrops use perception during fasting <i>B.S. Zulkarnain, Sumarno, Y. Nita &amp; R. Loebis</i>	375
Author index	381

Robert K. Chalmers Distinguished Educator Award. He has also received the Russell R. Miller Literature Award and the Education Award from ACCP. In 2013 he was the national Rho Chi Distinguished Lecturer. Dr. DiPiro was elected a Fellow in the American Association for the Advancement of Science. Dr. DiPiro is a past Editor of The American Journal of Pharmaceutical Education. He is an editor for *Pharmacotherapy: A Pathophysiologic Approach*, now in its 10th edition. He is also the author of *Concepts in Clinical Pharmacokinetics* and Editor of the *Encyclopedia of Clinical Pharmacy*. He has published over 200 journal papers, books, book chapters, and editorials in academic and professional journals.




Prof. Charles F. Lacy—*Professor of Pharmacy Practice and Vice President of Roseman University of Health Sciences, Henderson, Nevada, USA*

Prof. Charles F. Lacy, Pharm.D., MS., FASHP, FCSHP, BCPP, CAATS is Professor of Pharmacy Practice and Vice-President of Roseman University of Health Sciences. He co-founded the university with his co-founders, Dr. Renee Coffman (President) and Dr. Harry Rosenberg (President emeritus). He has practiced clinical pharmacy and taught at numerous universities over the past 35 years. He was the Clinical Coordinator of Pharmacy Services at Cedars-Sinai for 20 years. He has specialized in numerous areas over the years, including psychiatric and neurologic pharmacy, oncology and informatics. He is the lead author of the renowned "Drug Information Handbook" and lead editor of the Lexi-Comp Clinical Reference Library. Dr. Lacy is a recognized leader in Pharmacy- he has worked with numerous Pharmacy & Therapeutics (P&T) Committees at the state and national level,

and has lead focus groups and task-forces in the areas of pharmacoeconomics, team building, complementary medicine, and medication therapy management throughout much of the world.

## Plenary speakers



Prof. Michael D. Katz—*Professor at Department of Pharmacy Practice & Science, The University of Arizona College of Pharmacy, USA*

Prof. Michael D. Katz is Professor at the University of Arizona College of Pharmacy Department of Pharmacy Practice & Science. He practices at the University of Arizona Medical Center within the Department of Internal Medicine. His practice interests include general internal medicine, endocrinology, HIV/AIDS, infectious diseases, and evidence-based practice. Dr. Katz teaches pharmacy and medical students in both the classroom and experiential settings. He was selected in 2001 as a Dean's Teaching Scholar by the Arizona Health Sciences Center and has received numerous teaching awards. He is a Past-Chair of the American Society of Health-System Pharmacists (ASHP) Commission on Therapeutics. Dr. Katz has numerous publications and including *Pharmacotherapy Principles and Practices Study Guide: A Case-Based Care Plan Approach*, now in its fourth edition.

Dr. Katz is the Internal Medicine PGY2 Residency Program Director and directs all residency-related activities for the College of Pharmacy. He has been involved in international education and practice for even 15 years and he serves as the College of Pharmacy's Director of International Programs. In 2010 he received the University of Arizona's prestigious Excellence in International Education Award. He has consulted and lectured extensively in Japan and many other countries regarding pharmacy education and clinical pharmacy practice and he serves as the Co-Chair of the Board of Directors of the U.S.—Thai Pharmacy Consortium. Dr. Katz directs the largest program of its kind to train clinical pharmacy faculty members from Saudi Arabia.



Dr. Umi Athiyah—*Prof of Department of Pharmacy Practice and Dean of Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia*

Dr. Umi Athiyah is the current dean of Faculty of Pharmacy at University of Airlangga, Indonesia. Dr. Athiyah teaches various subjects including Pharmaceutical Philosophy, Community Pharmacy, Law and Ethics in Pharmacy, Management of Pharmacy Services and Logistics, Professional Communication, Pharmacoeconomics, Information Technology and Pharmaceutical Marketing. She has a research interest in Pharmacy Practice and Health Care System. She has been involved in many community based services. She has been invited as a speaker both in national and international conferences. She is one of the co-authors of a Pharmacy Management handbook.



Prof. Alan Lau—*Professor of Pharmacy Practice and Director of International Clinical Pharmacy Education at the University of Illinois at Chicago (UIC) College of Pharmacy, USA*

Prof. Alan Lau is Professor of Pharmacy Practice and Director of International Clinical Pharmacy Education at the University of Illinois at Chicago (UIC) College of Pharmacy. He obtained his Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees at the State University of New York at Buffalo and then completed a clinical pharmacy residency at UIC. He pioneered the development of clinical pharmacy services for renal failure patients on dialysis. Dr. Lau had obtained many research grants for clinical and laboratory research in renal pharmacotherapeutics and clinical pharmacology, with a recent focus on mineral and bone disorder in chronic kidney disease. He has published many research papers and book chapters, including chapters in the textbooks *Pharmacotherapy, Applied Therapeutics—*

*The Clinical Use of Drugs and Basic Skills in Interpreting Laboratory Data*. Dr. Lau was one of the founding members of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. In addition, he had served on the Board of Director and as Chairman of the Renal Scientific Section in the American Society for Clinical Pharmacology and Therapeutics. Dr. Lau was elected to be vice-chairman of the Nephrology/Urology Expert Committee of United States Pharmacopeia (USP) in 2007. In 2010, he was elected as a Distinguished Practitioner to the National Academies of Practice in Pharmacy. Since 2011, Dr. Lau has been working with the American College of Clinical Pharmacy on international program development and is now the International Program Director. He also has been appointed guest professor/faculty at the National Taiwan University, University of Hong Kong, University of Malta and also the Central South University in Changsha, China. Dr. Lau has been invited to give lectures on pharmacotherapy and clinical pharmacy service development in many countries, including Japan, South Korea, China, Hong Kong, Taiwan, Thailand, Vietnam, Malaysia, Singapore, Philippines, Indonesia, Saudi Arabia, Turkey and Malta.



Prof. Roger Lander—*Professor of Pharmacy Practice at Samford University, in Birmingham, Alabama, USA*

Prof. Roger Lander currently serves as Professor of Pharmacy Practice at Samford University, in Birmingham, Alabama, USA. He received his B.S. in Pharmacy and Pharm.D. from the University of Missouri-Kansas City and completed a clinical pharmacy residency program at Truman Medical Center. He then served as a faculty member at UMKC's Schools of Medicine and Pharmacy. Moving to Samford in 1986, he has developed practices in adult medicine, nutrition, ambulatory care, and pharmacokinetics. He previously served as Vice-Chair, Chair and Assistant Dean for Practice Programs. In 1994, Professor Lander helped develop a clerkship for Samford students at Guy's and St. Thomas' Hospitals in London and assisted the pharmacy there in the development of their ambulatory anticoagulation services. Professor Lander helped establish Samford's faculty/student

exchange program with Meijo University in Nagoya, Japan and has traveled widely throughout Asia for information exchange and to assist colleges and hospitals in their clinical teaching and practice. He helped develop study opportunities at Samford for pharmacists from England, Japan, Korea, China, Malaysia, Indonesia, and Vietnam. Dr. Lander is one of the founders of the Asian Conference on Clinical Pharmacy. He has traveled to Indonesia at least a dozen times to assist pharmacists in their practice development.

## List of symposium speakers

### SYMPOSIUM 1: DEVELOPING CLINICAL PHARMACY

- Prof. Charles D. Sands—*Former Dean and Professor (retired), McWhorter School of Pharmacy, College of Health Sciences, Samford University, Birmingham, Alabama, USA*
- Dr. Surakit Nathisuwan—*Associate Professor in Clinical Pharmacy in Clinical Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand*
- Ms. Nor Hasni Bt Haron—*Senior Principal Assistant Director Pharmaceutical Services Division, Ministry of Health of Malaysia*
- Dr. Budi Suprapti—*AlProf at Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga. Head of Pharmacy Department at Universitas Airlangga Teaching Hospital, Surabaya, Indonesia*
- Dr. Margaret Choye—*Clinical Assistant Professor at College of Pharmacy, the University of Illinois at Chicago, USA. Clinical Pharmacist in Internal Medicine at the University of Illinois at Chicago Hospital and Health System, USA*

### SYMPOSIUM 2: ADVANCED PRACTICE 1

- Dr. Hiroyuki Kamei—*Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan*
- Dr. Hanna Sung—*University of the Pacific, Thomas J. Long, School of Pharmacy and Health Sciences in California, USA*
- Dr. Alexandre Chan—*Deputy Head and a tenured Associate Professor at the Department of Pharmacy, Faculty of Science at National University of Singapore (NUS) and the Duke-NUS Medical School, Singapore*
- Prof. Jae Wook Yang—*Professor and Director of the Institute of Clinical Research and Practice, College of Pharmacy, Sahmyook University & Vice President of Korean College of Clinical Pharmacy*
- Prof. Dr. Syed Azhar Syed Sulaiman—*Professor at School of Pharmaceutical Sciences at University Sains Malaysia, Penang, Malaysia*

### SYMPOSIUM 3: MOLECULAR PHARMACOLOGY AND PHARMACOGENOMICS

- Dr. Mehdi Rajabi—*Clinical Pharmacy and Pharmacy Practice, Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, Iran. Clinical Pharmacist, Member of General Pharmaceutical Council of Great Britain*
- Mrs. Fan Zhang—*Lanzhou University, a Pharmacist-in-Charge at Pharmacy Department of the First Hospital of Lanzhou University in China*
- Dr. Lunawati Bennet—*Assoc. Professor of Pharmaceutical Sciences at Union University School of Pharmacy in Jackson, Tennessee, USA*
- Prof. Robert D. Sindelar—*Professor and former Dean of Faculty of Pharmaceutical Sciences, University of British Columbia; and Advisor, External relations, Centre for Health Evaluation & Outcomes Sciences (CHEOS), Providence Health Care research Institute and University of British Columbia, Canada*
- Dr. Baharudin Ibrahim—*School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia*

#### SYMPOSIUM 4: INTERPROFESSIONAL EDUCATION

- Dr. Christine B. Teng—*Assoc. Professor of Department of Pharmacy, National University of Singapore Principal Pharmacist (Clinical), Dept of Pharmacy, Tan Tock Seng Hospital, Singapore*
- Mr. Tan Wee Jin—*Principle Pharmacist at Guardian Health & Beauty, Singapore*
- Dr. Ching Jou Lin—*Senior lecturer in the Discipline of Social and Administrative Pharmacy, University Sains Malaysia, Malaysia*
- Mr. Mac Ardy J. Gloria—*University of the Philippines, The Philippines*
- Dr. Vivian Lee Wing Yan—*Assoc. Professor of the School of Pharmacy and the Assistant Dean (Student Development) of the Faculty of Medicine, Chinese University of Hong Kong*

#### SYMPOSIUM 5: ADVANCED PRACTICE 2

- Prof. Timothy E. Welty—*Professor and Chair of Clinical Science in the College of Pharmacy and Health Sciences at Drake University, Iowa, USA*
- Dr. Takao Shimazoe—*Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan*
- Prof. Zhou Quan—*Professor and Vice Dean of Department of Pharmacy, The Second Affiliated Hospital of Zhejiang University, China*
- Prof. Sukhyang Lee—*Professor of Clinical Pharmacy at College of Pharmacy, Ajou University, Korea*
- Prof. Kheirollah Gholami—*Professor and Chairman at the Department of Clinical Pharmacy, College of Pharmacy, Iran*

#### SYMPOSIUM 6: HEALTH CARE DELIVERY IN COMMUNITY PHARMACY

- Prof. Michael D. Hogue—*Assoc. Dean for the Center for Faith and Health at Samford University's College of Health Sciences, Birmingham, Alabama, USA*
- Dr. Elida Zairina—*Senior lecturer of Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia*
- Ms. Leonila M. Ocampo—*Chairman of the Hygieian Insitute for Education, research and Training Inc, The Philippines*
- Ms. Yong Pei Chean—*Senior Manager, Khoo Teck Puat Hospital and Council Member, Pharmaceutical Society of Singapore*
- Drs. Saleh Rustandi—*Chairman of Himpunan Seminar Farmasi Masyarakat (HISFARMA) of Indonesia*

#### SYMPOSIUM 7: PHARMACY EDUCATION

- Dr. Takashi Egawa—*Clinical Pharmaceutics and Health Sciences, Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan*
- Prof. Yolanda R. Robles—*Professor and former Dean College of Pharmacy, University of the Philippines*
- Prof. Rong-sheng Zhao—*Professor in Peking University Third Hospital, China. Assistant to President, Deputy-Director in Pharmacy Department of Peking University Third Hospital, China*
- Dr. Mani Saetewa—*Staff of Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Thailand*
- Drs. Nurul Falah Eddy Pariang—*President of Indonesian Pharmacist Association, Indonesia*
- Prof. Joseph T. Dipiro—*Dean, Professor and Archie O. McCalley Chair at the Virginia Commonwealth University, School of Pharmacy, Richmond, Virginia, USA*

#### SYMPOSIUM 8: ADVANCED PRACTICE 3

- Dr. Daraporn Rungprai—*Academic Staff of Faculty of Pharmacy, Silpakorn University, Thailand*
- Ms. Hong Yen NG—*President, 110th Council, Pharmaceutical Society of Singapore Specialist Pharmacist (Oncology), Singapore General Hospital*
- Prof. Agung Endro Nugroho—*Professor of Department of Pharmacology and Dean of Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia*

- Dr. Farshad Hashemian—*Assoc. Professor at Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, Iran*
- Dr. Junaidi Khotib—*Assoc. Professor of Department of Clinical Pharmacy at Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia*

#### SYMPOSIUM 9: IMPROVING PATIENT MEDICATION SAFETY

- Dr. Wimon Anansakunwatt—*Siriraj Hospital, Thailand*
- Mr. Mohammed Nazri Abdul Ghani—*Principal Pharmacist and Medication Safety Officer (MSO) of KK Women's & Children Hospital, Singapore*
- Ms. Yoon Sook Cho—*Director of Pharmacy Department, Seoul National University Hospital, Korea*
- Dr. Sutthiporn Pattharachayakul—*Assistant Professor at the Department of Clinical Pharmacy, Prince of Songkla University, Thailand*
- Dra Mariyatul Qibtiyah—*Head of Paediatric Pharmacy Services at Dr Soetomo Hospital, Surabaya, Indonesia*
- Prof. Charles F. Lacy—*Professor of Pharmacy Practice and Vice President of Roseman University of Health Sciences, Henderson, Nevada, USA*



## The effect of Telmisartan on lipid levels and proinflammatory cytokines in ESRD patients undergoing hemodialysis

B. Suprapti, W.P. Nilamsari, Z. Izzah & M. Dhrik

Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia  
Department of Pharmacy, Airlangga Teaching Hospital, Surabaya, Indonesia

B. Dharma

Bhayangkara General Hospital, Surabaya, Indonesia

**ABSTRACT:** Telmisartan acts as a partial selective agonist of PPAR $\gamma$ , thus might affect lipid and carbohydrate metabolisms. This study aimed to investigate the effect of Telmisartan on lipid profiles and Proinflammatory Cytokine (CRP) in ESRD patients. An observational study was conducted on ESRD patients with regular hemodialysis at least twice a week during the last three months, blood pressure predialytic >140/90 mmHg, and not using Telmisartan. Sixteen subjects were involved (12 male and four female). Pre-study levels of cholesterol, TG, HDL and LDL were normal. After three months of treatment with Telmisartan, the levels of cholesterol, TG, HDL and LDL were 127.31 mg/dl, 74 mg/dl, 50.06 mg/dl and 74.56 mg/dl, respectively, showing a decrease in lipid levels except for cholesterol. The level of CRP was slightly decreased after Telmisartan treatment from  $0.47 \pm 0.47$  mg/dl to  $0.34 \pm 0.33$  mg/dl. Thus, Telmisartan has a promising effect on decreasing lipid and cytokine proinflammatory levels in ESRD patients with hemodialysis.

### 1 INTRODUCTION

Increasing prevalence of end stage renal disease (ESRD) highly contributes to the cardiovascular complication event (47%) (Pernefri 2012). One of the comorbid conditions that play an important role in causing cardiovascular complication in ESRD is hypertension. On the other hand, the activation of renin angiotensin aldosterone system (RAAS) and insulin resistance through proinflammatory cytokines (IL-1, IL-6, TNF- $\alpha$ , etc), visceral adipose tissue, adipokines metabolism dysregulation (leptin, adiponectin, resistin), metabolic acidosis, hyperparathyroidism, anemia, other oxidative stress factors and uremia toxin are also responsible for cardiovascular complications (Hung & Ikizler, 2011).

There are several pharmacological agents that have been developed to reduce insulin resistance by increasing insulin sensitivity, e.g. biguanide and thiazolidinedione (O'Toole et al. 2012). Unfortunately, they are contraindicated in patients with ESRD. Recent research has reported that the metabolic effect of an Angiotensin II receptor blocker (ARB), Telmisartan, has a unique pharmacological characteristic by its affinity for Angiotensin II Receptor-1 (ATR-1), but not for other receptors (adenosine, adrenergic, dopaminergic, endothelin,

histamine, muscarinic, neurokinin, neuropeptide Y, or serotonergic). Telmisartan is a partial selective agonist on PPAR $\gamma$ , which regulates lipid and carbohydrate metabolism. There are studies showing the ability of Telmisartan on improving insulin resistance by decreasing plasma insulin and HOMA IR (Kurtz & Pravenec 2004). Other parameters to indicate the existence of insulin resistance are lipid profile and proinflammatory cytokines level. This research aimed to examine the effect of Telmisartan on lipid profiles and inflammatory marker in patients with ESRD and hypertension.

### 2 MATERIAL AND METHOD

#### 2.1 Study design

It was an observational research with a cohort prospective method aimed to investigate the Telmisartan effects on lipid profiles (cholesterol, LDL, HDL and TG), and inflammatory marker (CRP) on hemodialysis patients with hypertension.

#### 2.2 Subject

Subject of present study were patients with ESRD and hypertension (HT) undergoing regular hemodialysis (HD) and fulfilling the inclusion criteria

including: (1) is undergoing regular HD with minimum twice a week during the last three months; (2) has pre-dialysis blood pressure >140/90; (3) the first time of consuming Telmisartan; (4) is willing to join the research and has signed the informed consent. The subjects' exclusion criterion was the subject who has fasting blood glucose >130 mg/dL. Dropout criteria were as follows: non-compliance, allergic, and/or suffering from medicine side effects; subjects were no longer going to undergo hemodialysis; patient died during the research. The number of samples in the present study was 15-20 subjects (pilot research).

### 2.3 Sampling technique

Sampling technique in this research was using non-probability-sampling with consecutive sampling method.

### 2.4 Statistical analysis

The data were statistically analyzed by paired t-test and/or Wilcoxon test.

## 3 RESULT AND DISCUSSION

There were 16 subjects (12 men and four women) recruited in HD Unit Bhayangkara Hospital Surabaya. The average of the subject age and Body Mass Index (BMI) were 45 years old and 22.85, respectively. The distribution of sexes, ages and BMI are shown in Table 1.

The lipid profiles examined in the present study were cholesterol, HDL, LDL and triglycerides. In the beginning of the study, it was found that the mean levels of cholesterol, TG, HDL and LDL were in normal range, which were 154.88 mg/dl, 82.44 mg/dl, 42.69 mg/dl, and 90.44 mg/dl, respectively (Table 2). However, there were two patients with cholesterol, TG and LDL above normal limit. After three months of treatment with Telmisartan, the mean levels of cholesterol, TG, HDL and

Table 1. The demographic data of the subjects.

Characteristics	Result		
	Number	Percentage (%)	
Sex	Men	12	75
	Women	4	25
Age	20-40	6	37.5
	40-60	10	62.5
BMI	18.5-25	13	81.25
	25-30	3	18.75

Table 2. Lipid profile at pre- and post-therapy of Telmisartan.

Sample		Median $\pm$ SD		p value
		Range		
Cholesterol	Pre	154.88 $\pm$ 33.86 mg/dl	244-85 mg/dl	p = 0.001
	Post	127.31 $\pm$ 21.85 mg/dl	182-84	
TG	Pre	82.44 $\pm$ 39.49 mg/dl	230-27 mg/dl	p = 0.187
	Post	74.00 $\pm$ 34.38 mg/dl	192-20 mg/dl	
HDL	Pre	42.69 $\pm$ 9.23 mg/dl	73-24 mg/dl	p = 0.011
	Post	50.06 $\pm$ 7.06 mg/dl	70-36 mg/dl	
LDL	Pre	90.44 $\pm$ 24.12 mg/dl	172-52	p = 0.010
	Post	74.56 $\pm$ 15.13	118-44	

LDL were 127.31 mg/dl, 74 mg/dl, 50.06 mg/dl and 74.56 mg/dl, respectively. Since the distribution of the data was normal, paired t test was conducted to determine the statistical difference in the level of cholesterol, HDL and LDL. The present study showed that Telmisartan therapy for three months significantly decreased cholesterol, HDL and LDL in patients with ESRD and hypertension ( $p < 0.001$ ). On the other hand, since the data distribution of triglycerides was not normal, we conducted Wilcoxon test. P value was 0.043 ( $p < \alpha$ ,  $\alpha = 0.05$ ) indicating Telmisartan therapy for three months did not significantly decrease triglyceride level.

The mean level of CRP before Telmisartan therapy was normal (0.47 mg/dl; Fig. 1). After a 3-month Telmisartan therapy, the mean level of CRP decreased to 0.34 mg/dl. However, there are six subjects (37.5%) with an increase CRP level. Wilcoxon test showed that there was no statistical difference between CRP level in pre- and post-therapy with Telmisartan ( $p = 0.437$ ; Figure 1).

Telmisartan activities on insulin resistance, lipid profiles, and inflammation are based on its ability as agonis parsial PPAR $\gamma$ . PPAR $\gamma$  is one of the receptors for nuclear hormone that play an important role as transcription factor in the regulation of carbohydrate metabolism, lipid metabolism, and inflammation. PPAR $\gamma$  is commonly expressed in adipocyte tissue and smaller expression in vascular smooth muscle cells, endothelium, and monocytes (Kurtz & Pravenec 2004). The activity of Telmisartan is closely related to the molecular structure




Figure 1. CRP profile at pre- and post-therapy with Telmisartan.

resembling pioglitazone, one of thiazolidinedione. Telmisartan exhibits 25–30% of pioglitazone ability to activate PPAR $\gamma$  (Kurtz & Pravenec 2004).

The activation of PPAR $\gamma$  increases the expression of many kinds of genes as well as enzymes related to carbohydrate metabolism (adiponectine, glucokinase, GLUT-4 glucose transporter) and lipid metabolism (lipoprotein lipase, adipocyte fatty acid transporter protein, fatty acyl CoA synthase, malic enzyme). Likewise, the activation of PPAR $\gamma$  suppresses the activity of inflammatory factor TNF- $\alpha$ , which suppresses insulin sensitivity through insulin signal transduction disorders (Bouskila et al. 2005).

The decrease in insulin resistance shown by the notable changes in most of the lipid profiles (LDL, HDL, cholesterol) after 3-months therapy with Telmisartan demonstrates the theoretical hypothesis on the activity of Telmisartan on PPAR $\gamma$ . This activity on PPAR $\gamma$  showed that Telmisartan potentially affects the regulation of carbohydrate metabolism, lipid metabolism and inflammation (Kurtz & Pravenec 2004). However, the present study failed to show a suppressing effect of Telmisartan on CRP level.

CRP is one of the main inflammatory markers related to cardiovascular mortality and infection on patients with HD (Kawaguchi et al. 2011). The increase of CRP level in ESRD subjects is particularly caused by chronic inflammation and oxidative stress. However, low albumin serum, calcium level, high BMI and uric acid may also play important roles in increasing CRP level (Kawaguchi et al. 2011). Thus, the inadequate effect of Telmisartan on improving CRP level in the present study might be caused by other factors that were not well controlled before the study.

#### 4 CONCLUSION

From the present study, it can be concluded that Telmisartan has a promising prospect to be used for decreasing lipid profiles in patients with ESRD. Further study is needed to strengthen the present findings.

#### REFERENCES

- Hung, A.M. and Ikizler, T.A. 2011. Factors determining insulin resistance in chronic hemodialysis patients. In *Contributions to nephrology*.
- Kawaguchi, T., Tong, L., Robinson, B.M., Sen, A., Fukuhara, S., Kurokawa, K., Cansaud, B., Lameire, N., Port, F.K. and Pisoni, R.L. 2011. C-Reactive protein and mortality in hemodialysis patients: The dialysis outcomes and practice patterns study (DOPPS). *Nephron Clinical Practice* 117(2): c167-c178.
- Kurtz, T.W. and Pravenec, M. 2004. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist: beyond the renin-angiotensin system. *Journal of Hypertension* 22 (12): 2253–2261.
- O'Toole, S.M., Fan, S.L., Yaquob, M.M. and Chowdhury, T.A. 2012. Managing diabetes in dialysis patients. *Postgraduate Medical Journal* 88 (1037):160–166.
- Pernefri. 2012. *5th Report of Indonesian renal registry*.
- Takenaka, T., Kanno, Y., Ohno Y. and Suzuki, H. 2007. Key role of insulin resistance in vascular injury among hemodialysis patients. *Metabolism Clinical and Experimental* 56 (2): 153–159.



SK SKP :  
201/SK-SKP/PP.IAI/II/2017  
Moderator : 1.5 SKP  
Judge : 4.5 SKP  
Presenter : 4.5 SKP

# Certificate of Participation

Awarded to:

## Budi Suprapti

### Poster Presenter

who has contributed as .....

in the 20 Years of ACCP: 17th Asian Conference on Clinical Pharmacy  
"Unity in Diversity and the Standardisation of Clinical Pharmacy Services"  
held on July 28-30, 2017 in **Yogyakarta - Indonesia**

**Dr. Yunita Nita, M.Pharm., Apt.**  
President of Asian Conference on Clinical Pharmacy

**Dr. Umi Athiyah, M.S., Apt.**  
Dean of the Faculty of Pharmacy, Universitas Airlangga

**Drs. Nurul Falah Eddy Pariang, Apt.**  
President of Indonesian Pharmacist Association